Parabilis Medicines, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Parabilis Medicines, Inc. now
Current reporting with the operating signal separated from the noise.
Parabilis Medicines, Inc. (PBLS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
The story matters when it changes Parabilis Medicines, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Why Parabilis Medicines, Inc.’s (PBLS) Stock Is Down 5.03%
Investors are testing whether Parabilis Medicines, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Parabilis Medicines, Inc.: Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Investors are testing whether Parabilis Medicines, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest PBLS filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Parabilis Medicines, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →